Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on PF-06372865 PK in Healthy Adults
NCT02475746Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darigabat in epilepsy, anxiety disorder and chronic low back pain (CLBP), sponsored by Pfizer. Primary endpoints: Cmax ratio of PF-06372865 alone vs coadministration with itraconazole, AUC ratio of PF-06372865 alone vs coadministration with itraconazole and 4 more. Planned start Jul 2015; status: withdrawn.
02
Drugs
darigabat
03
Conditions
epilepsyanxiety disorderchronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT02475746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475746.